Neoadjuvant nivolumab plus chemotherapy improves overall survival in resectable NSCLC



Summary

Neoadjuvant nivolumab combined with chemotherapy significantly improves overall survival (OS) in patients with resectable non-small cell lung cancer (NSCLC) compared to chemotherapy alone. This conclusion comes from the CheckMate 816 trial’s final analysis, showing a statistically significant and clinically meaningful OS benefit with the immunotherapy combination. These results solidify neoadjuvant nivolumab plus chemotherapy as a standard treatment option for resectable NSCLC, offering patients a greater chance of long-term survival. The study confirms prior findings on pathological complete response and event-free survival, further supporting the efficacy of this approach.

Read more…

This post is part of “Science/Immunology News”, Follow for more…!!!